(Q38549355)

4 September 2017

1 reference

title

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias (English)

1 reference

4 September 2017

0 references

1 reference

H S Yee

1

1 reference

PubMed ID

9793596

4 September 2017

N T Fong

series ordinal

2

1 reference

PubMed ID

9793596

4 September 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

Annals of Pharmacotherapy

4 September 2017

1 reference

4 September 2017

32

1 reference

4 September 2017

10

1 reference

4 September 2017

1030-1043

1 reference

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

4 September 2017

1 reference

Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

21 January 2018

1 reference

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

21 January 2018

1 reference

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 January 2018

1 reference

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

21 January 2018

1 reference

Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)

21 January 2018

1 reference

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

21 January 2018

1 reference

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

21 January 2018

1 reference

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

21 January 2018

1 reference

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

21 January 2018

1 reference

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

21 January 2018

1 reference

Cholesterol is required for secretion of very-low-density lipoprotein by rat liver

21 January 2018

1 reference

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

21 January 2018

1 reference

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

21 January 2018

1 reference

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

21 January 2018

1 reference

Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.

21 January 2018

1 reference

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

21 January 2018

1 reference

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

21 January 2018

1 reference

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

21 January 2018

1 reference

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction

21 January 2018

1 reference

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

21 January 2018

1 reference

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

21 January 2018

1 reference

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.

21 January 2018

1 reference

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

21 January 2018

1 reference

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

21 January 2018

1 reference

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17231

1 reference

4 September 2017

1 reference

PubMed ID

9793596